Browse life science companies in Cambridge, home to one of Europe's leading biotechnology and life science ecosystems.
Targeted oncology combination therapies in biomarker-defined cancer populations
Mosaic Therapeutics is a Cambridge biotech developing targeted combination therapies for cancer. Its proprietary platform integrates genome-scale CRISPR screening, high-throughput combination drug testing across over 1,300 patient-derived tumour models, and advanced computational analysis to identify synergistic drug…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The company's approach focuses on blocking microglial dysfunction to restore toxin clearance in the brain. Founded by NLRP3 inflammasome expert Matt…
Human iPSC models and AI phenomics for drug discovery
Pixl Bio combines human induced pluripotent stem cell (iPSC) models with AI-driven image analysis for drug discovery and safety research. Its portfolio includes liver cells, stellate cells and disease models, alongside CRISPR engineering, high-content Cell Painting and contract studies. These tools help researchers…
Veterinary vaccine R&D and licensing for livestock infectious diseases
Cambivac develops and licenses veterinary vaccine technologies, combining genomic research with traditional virology and molecular approaches. Its documented development programmes include vaccines for foot-and-mouth disease and porcine reproductive and respiratory syndrome, a respiratory disease affecting pigs. The…
Whole genome synthesis platform engineering novel therapeutic biomolecules
Constructive Bio is a Cambridge-based synthetic biology company developing programmable biology platforms for the creation of novel biomolecules. Spun out of the MRC Laboratory of Molecular Biology, the company's technology combines whole genome synthesis and engineered protein translation to produce molecules…
Automated benchtop instrumentation for rapid protein and viral vector quantification
Abselion develops automated analytical instrumentation for biomolecule quantification in biopharmaceutical research and manufacturing. Its technology enables rapid quantification of antibodies, AAVs and other proteins directly from crude samples without optics or fluidics. The platform is designed for at-line use in…
AI-native platform for cell culture process design and optimisation
Tolemy Bio Ltd is a company developing an AI-native platform for cell therapy process development and manufacturing optimisation. The platform ingests experimental and bioreactor data including cell growth, phenotype, potency, and metabolite profiles, then applies causal AI models to identify the biological drivers of…
Clinical genomic decision support software for rare disease and oncology
Congenica is a clinical genomic interpretation platform spun out of the Wellcome Sanger Institute. Its software supports variant analysis and clinical reporting across rare disease, oncology and infectious disease, integrating whole genome sequencing data with phenotypic information to generate actionable diagnostic…
Microfluidic instruments for protein interaction and single-cell analysis
Fluidic Sciences is a company developing and supplying instruments for biopharmaceutical research, combining two complementary technology platforms. Its core offering covers in-solution protein interaction characterisation without immobilisation, alongside a high-throughput picodroplet platform for single-cell…
Integrated CRO services from drug discovery to manufacture
Charles River Laboratories is a global contract research organisation providing integrated preclinical drug discovery and development services to pharmaceutical, biotechnology and academic clients. UK operations span multiple sites offering medicinal chemistry, biology, ADME/PK, structural biology, immunology, in vivo…
Chromatography resins and bioseparation technologies for biomanufacturing
Astrea Bioseparations develops and manufactures chromatography resins, adsorbents, columns and nanofiber-based purification technologies for the biopharmaceutical and advanced therapeutics industries. Its portfolio supports downstream bioprocessing including affinity purification, host cell protein removal, viral…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Enterprise biopharma software for discovery, analytics and development
Genedata is a scientific software company supplying enterprise platforms for biopharmaceutical research and development. Its systems manage and analyse high-throughput screening, biologics discovery, mass spectrometry, next-generation sequencing, bioprocess development and manufacturing data. They connect laboratory…
Modular microfluidic and automation systems for autonomous biology labs
Engivent develops modular microfluidic hardware and automation software for biological laboratories. Its platform combines microfluidic chips, laboratory robotics, sensing and structured data capture into programmable experimental workflows. The company is building towards closed-loop systems in which results inform…
Proprietary phage display platform for therapeutic antibody discovery
RxBiologics is a Cambridge-based antibody discovery CRO and subsidiary of RxCelerate. Its proprietary phage display library platform incorporates in-line optimisation technology modelled on B cell affinity maturation, designed to generate clinic-ready antibody candidates with drug-like properties from first selection.…
Engineering microbes to produce bio-based chemicals from waste feedstocks
17Cicada is an industrial biotechnology company engineering non-conventional microbial chassis, including cyanobacteria and Streptomyces, to produce bio-based chemicals and biomass from waste feedstocks and CO₂. The company applies synthetic biology and low-carbon fermentation processes to create value from…
Off-the-shelf cell therapies for cancer and rare diseases
Empyrean Therapeutics develops off-the-shelf cell therapies intended to make treatments for cancer and rare diseases more accessible. Its approach combines gene editing, stem cell programming and precise genetic control to engineer therapeutic cells. The company is developing cell platforms and manufacturing processes…
AI-driven delivery platform for siRNA therapies beyond the liver
Undecimal Bio is a biotechnology company developing targeted delivery technologies for small interfering RNA (siRNA) therapeutics beyond the liver. Its DELiveri platform combines large-scale combinatorial chemistry, functional cell-based screening and AI to identify synthetic conjugates that transport siRNA into…
Targeted antibacterial gel for gum disease
Sysora Health develops a targeted antibacterial gel for periodontitis, a severe form of gum disease. Its approach aims to eliminate Porphyromonas gingivalis, a bacterium implicated in gum inflammation, while preserving beneficial microorganisms in the oral microbiome. The company is investigating selective bacterial…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule scaffold into two loops, conferring high-affinity target binding with the tissue penetration of small molecules. Its lead programme, a…